Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (Abstract 1001).
Francesca M. Gay, MD, of GIMEMA, European Myeloma Network, discusses study findings on the use of carfilzomib in induction combination regimens with autologous transplantation, and...
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Merav Bar, MD, of the Fred Hutchinson Cancer Research Center, discuss study findings on the ...
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study findings on rivaroxaban thromboprophylaxis in high-risk ambulatory patients, which showed a reduction in venous thromb...
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses phase III study findings on luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysp...
Paul Richardson, MD, of Dana-Farber Cancer Institute, discusses updated results and the first report on progression-free survival for melflufen therapy administered to people with ...